Current Report Filing (8-k)
August 09 2018 - 3:39PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): August 4, 2018
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
DELAWARE
|
|
000-51476
|
|
20-2903526
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
248
Route 25A, No. 2
East
Setauket, New York 11733
(Address
of principal executive offices)
(631)
942 7959
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (See General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02.
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
Effective
August 4, 2018 (the “Effective Date”), Dr. Yun Yen and Dr. Winson (Sze Chun) Ho were elected to the Company’s
Board of Directors. Each director is to receive five-year options to purchase an aggregate of 200,000 shares of the Company’s
Common Stock, vesting 100,000 shares on the Effective Date and 100,000 shares on the first anniversary of the Effective Date,
at an exercise price of $0.28 per share.
On
August 8, 2018, the Company issued a press release regarding the election of Drs. Yen and Ho to the Company’s Board of Directors.
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d)
There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits which exhibit is incorporated herein
by reference
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
August 9, 2018
|
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
|
|
|
|
|
By:
|
/s/
JOHN S. KOVACH
|
|
|
John
S. Kovach, Chief Executive Officer
|
INDEX
TO EXHIBITS